CNS Brain Metastasis, Esophageal Cancer, Head and Neck Cancer, Lung Cancer, Prostate Cancer
Conditions
Brief summary
Fractionated radiotherapy induces an observable change in the proliferative activity as assessed by pre-treatment and early-treatment 18F-FLT PET imaging. This study is designed to investigate 18F-FLT as a PET imaging agent for predicting treatment effectiveness in several tumors and will serve as a pilot study to a planned PO1 submission
Interventions
PROCEDUREImaging with 18F-FLT PET
Imaging with 18F-FLT PET
Sponsors
University of Wisconsin, Madison
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Able to tolerate a PET/CT scan * Age of 18 or older * signed informed consent * being considered for radiotherapy for treatment of CNS mets, Head and neck cancer, lung cancer, prostate cancer or esophageal cancer
Exclusion criteria
* Prior XRT to site being studied * severe claustrophobia or inability to tolerate PET/CT * unable to provide written consent * pregnant or breastfeeding women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To test whether the cellular response to fractionated radiotherapy leads to observable global change in the uptake of 18F-FLT as assessed by PET imaging | end of study |
Secondary
| Measure | Time frame |
|---|---|
| To assess the technical and logistic feasibility of 18F-FLT scans in a population of cancer patients | end of study |
Countries
United States
Outcome results
None listed